Abiomed, Inc. (ABMD) Valuation
Market multiples plus a Sirius Investors DCF: TTM revenue, EBIT, and FCF, then a 5-year bear / base / bull fair value versus the current price. Upgrade to unlock DCF fair value, reverse-DCF market pricing, and the full assumption set.
Unlock the full ABMD valuation model
See DCF fair value, what the market is pricing, assumption details, reliability scoring, and the 5-year FCFF bridge. Market multiples below stay free.
Already subscribed? Sign in
What would justify ABMD’s current price?
Reverse DCF — what the market must be assuming, given this forecast structure, for $381.02 to be fair. Fair value comes after this, not before.
Market-implied terminal EV/FCFF
What terminal multiple today’s price requires if the 5-year forecast holds.
Sirius implied terminal EV/FCFF
Gordon exit multiple from the base DCF assumptions.
| Metric | Sirius base | Required at $381.02 |
|---|---|---|
| Year-5 FCFF | ||
| Implied terminal EV/FCFF | ||
| Terminal growth | ||
| WACC | ||
| FCFF uplift vs base path |
Unlock reverse-DCF market pricing
See the terminal multiple and FCFF uplift today’s quote requires versus the Sirius base case.
Already subscribed? Sign in
Intrinsic valuation
5-year FCFF DCF. This is DCF-implied fair value under explicit assumptions — not a price target and not a claim that the stock cannot stay expensive. Quality compounders often trade above this model if the market uses a lower discount rate or prices in optionality.
DCF conclusion, reliability score, and valuation gap are available on paid plans.
Current price
$381.02
Base fair value
Valuation gap
Margin of safety
Bear / base / bull fair value
Unlock DCF fair value
See base / bear / bull fair value, the valuation gap versus today’s price, and model reliability.
Already subscribed? Sign in
Why this fair value
The number is only as good as these inputs. Disagree with an assumption and the fair value moves.
Year 1 revenue growth
EBIT margin path
WACC
CapEx / revenue
Terminal growth
Terminal value / EV
Implied terminal EV/FCFF
Normalized EBIT margin
Year-5 EBIT margin
Unlock model assumptions
See growth, margin path, WACC, CapEx intensity, and terminal-value drivers behind the fair value.
Already subscribed? Sign in
DCF reliability
How reliable this DCF is as an estimate of intrinsic value, given the predictability of future cash flows and how sensitive the model is to its assumptions. It is not a measure of how risky the company is, and it is not confidence that the stock will rise or fall.
Margin stability
Revenue growth uncertainty
Business-cycle & demand uncertainty
Terminal-value uncertainty
WACC sensitivity
Forecast uncertainty
Unlock DCF reliability score
See the 0–100 reliability score and the factor breakdown behind it.
Already subscribed? Sign in
Historical EBIT margins
Reported annual EBIT margins. Upgrade to see how the model translates this history into year-5 economics.
| Year | EBIT margin |
|---|---|
| TTM | 23.6% |
| 2022 | 36.1% |
| 2021 | 27.1% |
| 2020 | 29.6% |
| 2019 | 29.2% |
| 2018 | 26.5% |
| 2017 | 20.2% |
| 2016 | 19.8% |
| 2015 | 12.4% |
Market valuation
Multiples from TTM financials. They describe how the stock is priced, not whether that price is justified.
Market cap
17.18B
$381.02 × 0.05B shares
Enterprise value
16.36B
Market cap + debt − cash − short-term investments
P/E
64.4×
Market cap ÷ TTM net income
EV/EBITDA
34.8×
Enterprise value ÷ TTM EBITDA
P/S
16.0×
Market cap ÷ TTM revenue
Equity P/FCF
79.1×
Market cap ÷ TTM FCFF (equity multiple)
EV/FCFF
75.3×
Enterprise value ÷ TTM FCFF — comparable to the DCF terminal multiple
FCF yield
1.3%
TTM FCF ÷ market cap
P/S = 16.0× · P/E = 64.4× · equity P/FCF = 79.1× · EV/FCFF = 75.3×. Equity P/FCF and EV/FCFF are not interchangeable.
WACC × terminal growth sensitivity
Base case is highlighted. This is more honest than a single fair-value number: most of the DCF lives in these two assumptions.
| WACC \ g | 2.0% | 2.5% | 3.0% |
|---|---|---|---|
| Low | |||
| Base | |||
| High |
Unlock WACC × growth sensitivity
See how fair value moves across a company-specific WACC and terminal-growth grid.
Already subscribed? Sign in
5-year FCFF projection (base)
FCFF = NOPAT + D&A + CapEx (cash) + NWC (cash). CapEx is an outflow. NWC cash is negative when working capital absorbs cash and positive when it releases cash.
| Year | Revenue | EBIT margin | FCFF | PV of FCFF |
|---|---|---|---|---|
| 1 | ||||
| 2 | ||||
| 3 | ||||
| 4 | ||||
| 5 |
Unlock the 5-year FCFF bridge
See revenue, margins, CapEx, working capital, and present-value cash flows year by year.
Already subscribed? Sign in
Market cap & enterprise value history
Market Cap & Enterprise Value
Comparison of market capitalization and enterprise value over time
Market Cap
Enterprise Value
Market Cap History
Investor Valuation Insights
As of Aug 18, 2026EV/EBITDA
34.83x
Higher EV/EBITDA may imply premium pricing; growth durability should justify the multiple.
EV vs Market Cap Spread
-132.82M
EV is -0.9% vs equity value
Capital Structure Signal
Net Cash Profile
EV premium trend: +5.4 pp vs earliest data
Additional Multiples
EV/Sales: 15.23x
Net Debt/EBITDA: -1.75x
Share count change in dataset: +558.43%
Interpretation guide: EV/EBITDA compares total firm value (debt + equity - cash) to operating earnings. Lower is usually cheaper, but always benchmark against peers, growth rate, margins, and cyclicality.
Market Cap & Enterprise Value Data
Free users can view the latest 3 records. Upgrade to see full history.
| Date | Market Cap | Enterprise Value | Stock Price | Shares |
|---|---|---|---|---|
| Mar 31, 2022 | 15.05B | 14.92B | $331.24 | 45.45M |
| Mar 31, 2021 | 14.39B | 14.15B | $318.73 | 45.14M |
| Mar 31, 2020 | 6.56B | 6.37B | $145.16 | 45.18M |
Mar 31, 2019 | — | — | — | — |
Mar 31, 2018 | — | — | — | — |
Mar 31, 2017 | — | — | — | — |
Mar 31, 2016 | — | — | — | — |
Mar 31, 2015 | — | — | — | — |
Mar 31, 2014 | — | — | — | — |
Mar 31, 2013 | — | — | — | — |
Mar 31, 2012 | — | — | — | — |
Mar 31, 2011 | — | — | — | — |
Mar 31, 2010 | — | — | — | — |
Mar 31, 2009 | — | — | — | — |
Mar 31, 2008 | — | — | — | — |
Mar 31, 2007 | — | — | — | — |
Mar 31, 2006 | — | — | — | — |
Mar 31, 2005 | — | — | — | — |
Mar 31, 2004 | — | — | — | — |
Mar 31, 2003 | — | — | — | — |
Mar 31, 2002 | — | — | — | — |
Mar 31, 2001 | — | — | — | — |
Mar 31, 2000 | — | — | — | — |
Mar 31, 1999 | — | — | — | — |
Mar 31, 1998 | — | — | — | — |
Mar 31, 1997 | — | — | — | — |
Mar 31, 1996 | — | — | — | — |
Mar 31, 1995 | — | — | — | — |
Mar 31, 1994 | — | — | — | — |
Mar 31, 1993 | — | — | — | — |
Mar 31, 1992 | — | — | — | — |
Mar 31, 1991 | — | — | — | — |
Mar 31, 1990 | — | — | — | — |
Mar 31, 1989 | — | — | — | — |
Mar 31, 1988 | — | — | — | — |
Mar 31, 1987 | — | — | — | — |
Enterprise Value Analysis
Unlock analysisEnterprise-value insights and interpretation are included with Pro, Premium, and Enterprise.
Price Change (Mar 2021 to Mar 2022)
The stock price has increased from Mar 2021 to Mar 2022.
Recent Volatility
The stock price has been relatively volatile over the last 5 periods, indicating a higher risk profile.
Risk-Adjusted Return
The stock's returns compensate somewhat for its risk, suggesting a moderate investment opportunity.
Market Cap Change (Mar 2021 to Mar 2022)
The company's market capitalization has increased from Mar 2021 to Mar 2022.